Analysis of sulphadoxine/pyrimethamine resistance-conferring mutations of Plasmodium falciparum from Mozambique reveals the absence of the dihydrofolate reductase 164L mutant by Fernandes, Natércia et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Malaria Journal
Open Access Research
Analysis of sulphadoxine/pyrimethamine resistance-conferring 
mutations of Plasmodium falciparum from Mozambique reveals the 
absence of the dihydrofolate reductase 164L mutant
Natércia Fernandes*1, Paula Figueiredo2, Virgilio E do Rosário2 and 
Pedro Cravo3
Address: 1Departamento de Pediatria, Universidade Eduardo Mondlane/Faculdade de Medicina. Av. Salvador Allende, CP 257, Maputo, 
Mozambique, 2UEI Malária, Centro de Malária e Outras Doenças Tropicais/IHMT, Universidade Nova de Lisboa, Rua da Junqueira, 96 1349-008, 
Lisbon, Portugal and 3UEI Biologia Molecular, Centro de Malária e Outras Doenças Tropicais/IHMT, Universidade Nova de Lisboa, Rua da 
Junqueira, 96 1349-008, Lisbon, Portugal
Email: Natércia Fernandes* - naterciaf@yahoo.com.br; Paula Figueiredo - paulafigueiredo@ihmt.unl.pt; Virgilio E do 
Rosário - CMDT@ihmt.unl.pt; Pedro Cravo - pcravo@ihmt.unl.pt
* Corresponding author    
Abstract
Background: Plasmodium falciparum is the predominant human malaria species in Mozambique and
a lead cause of mortality among children and pregnant women nationwide. Sulphadoxine/
pyrimethamine (S/P) is used as first line antimalarial treatment as a partner drug in combination with
artesunate.
Methods: A total of 92 P. falciparum-infected blood samples, from children with uncomplicated
malaria attending the Centro de Saude de Bagamoyo in the Province of Maputo-Mozambique, were
screened for S/P resistance-conferring mutations in the pfdhfr and pfdhps genes using a nested
mutation-specific polymerase chain reaction and restriction digestion (PCR-RFLP). The panel of
genetic polymorphisms analysed included the pfdhfr 164L mutation, previously reported to be
absent or rare in Africa.
Results: The frequency of the S/P resistance-associated pfdhfr triple mutants (51I/59R/108N) and
of pfdhfr/pfdhps quintuple mutants (51I/59R/108N + 437G/540E) was 93% and 47%, respectively.
However, no pfdhfr 164L mutants were detected.
Conclusion:  The observation that a considerably high percentage of P. falciparum parasites
contained S/P resistance-associated mutations raises concerns about the validity of this drug as
first-choice treatment in Mozambique. On the other hand, no pfdhfr 164L mutant was disclosed,
corroborating the view that that this allele is still rare in Africa.
Background
Mozambique is included in the top ten nations most
affected by malaria, with Plasmodium falciparum being the
predominant species. Malaria is of stable transmission
and endemic in the entire country, making it the major
cause of morbidity and mortality across all age groups,
accounting for a third of all hospital deaths (USAID
Mozambique Country Strategic Plan, FY 2004–2010). The
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choice of appropriate therapeutic policies that circumvent
parasite chemoresistance has been one of the major chal-
lenges for malaria control nationwide. As the intensity of
chloroquine resistance increased, the country imple-
mented a change of first-line antimalarial treatment in
2002 to a combination of sulphadoxine/pyrimethamine
(S/P) + amodiaquine. In 2004, this has been further
altered to S/P + artesunate, in line with current WHO rec-
ommendations for the use of Artemisinin Combination
Therapies (ACTs) [1].
Sulphadoxine and pyrimethamine (S/P) act as synergistic
inhibitors of folate biosynthesis which, in malaria para-
sites, is an obligatory requirement for the production of
nucleotides and hence DNA synthesis. Because both com-
pounds act synergistically, any loss of efficiency in either
component results in the reduction of the effectiveness of
the combination as whole. In this context, the occurrence
of certain molecular polymorphisms in the dihydrofolate
reductase (pfdhfr) and dihydropteroate synthase (pfdhps)
genes have been associated to in vivo S/P treatment out-
come [2,3]. Particularly in East Africa, the occurrence of
the so-called pfdhfr/pfdhps  quintuple mutant parasites
(dhfr 51I/59R/108N + dhps 437G/540E) appears to be a
good predictor of S/P treatment failure [4,5].
Previous studies in Asia and South America have demon-
strated that pfdhfr mutants harboring a change from I to L
at position 164 in concert with 108N plus 51I and/or 59R
mutations present high-level resistance to both pyrimeth-
amine and cycloguanil [6,7]. It has been suggested that
this quadruple mutant has been selected through contin-
ued use of S/P in natural parasite populations [8-11]. For-
tunately,  P. falciparum I164L mutants have not
consistently been detected in Africa so far [12]. Neverthe-
less, because S/P is safe and cost-effective, its use in Africa
is growing either as first-line treatment alone or as a part-
ner drug within a combination, increasing the likelihood
of selection of I164L mutants. In face of such a scenario,
routine molecular surveillance will be needed to detect
the eventual emergence and propagation of this mutation.
The present work reports the prevalence of mutations in
codons 51, 59, 108 and 164 of the pfdhfr gene and in
codons 437 and 540 of the pfdhps gene among P. falci-
parum  samples collected from symptomatic malaria-
infected children from Maputo, Mozambique.
Methods
The study was conducted from July to October 2004,
among symptomatic children attending in Bagamoyo
Health Centre in Maputo City, Mozambique. One hun-
dred children with uncomplicated malaria were enrolled.
Inclusion criteria were i) monoinfection with P. falci-
parum, ii) no intake of antimalarial drugs during the last
three weeks, iii) no signs of complications (patients who
developed signs of complications were immediately trans-
ferred for adequate treatment and excluded from the
study), iv) no history of allergic reactions to sulphona-
mides, and v) informed consent of a parent or guardian.
The study was ethically reviewed and approved by the
"Comité Nacional de Bioética para a Saúde", the local Eth-
ics Committee. At each visit of the patients to the centre,
thin and thick blood films were prepared from finger-
pricked blood and 50 μl of blood were dotted on What-
man (Maidstone, United Kingdom) 3 MM filter paper and
air-dried at room temperature. The presence of P. falci-
parum in the peripheral blood was determined by micro-
scopical examination of thick blood films in slides stained
with 5% Giemsa solution. Parasite quantification was
done by calculating the percentage of P. falciparum-
infected red blood cells upon examination of thin blood
films prepared as above.
The preparation of parasite genomic DNA, nested muta-
tion-specific PCR and detection of point mutations at pfd-
hfr (codons 51, 59, 108 and 164) and pfdhps (codons 437
and 540) was done using previously published protocols
[13]. The frequency of mutant, wild-type and mixed gen-
otypes was assessed for each individual polymorphic
marker. To calculate the frequency of parasites carrying
multiple mutations, mixed genotypes were excluded in
order to maximize the probability that the observations
reflected genuine haplotypes and not a fictitious combi-
nation of mutations from different clones.
Results and discussion
Of a total one hundred children recruited into this study,
ninety two satisfied the inclusion criteria. The median age
of the 92 patients (50 female, 42 male) was 7.3 years
(range 3 months to 15 years). The geometric mean asexual
parasitaemia of P. falciparum was 2.33% (95% confidence
interval, 0.50–5.68).
The main observations resulting from the genotype anal-
yses are presented as allele frequencies and haplotype fre-
quencies in Table 1 and Figure 1, respectively. The
frequency of mutations unveiled for both genes was high:
81 out of 92 isolates harbored the dhfr 51I mutation, 82
of 90 were dhps 59R mutants and 87 out of 92 displayed
the 108N mutation (Table 1). Dhps mutants were less fre-
quent than dhfr ones, but already well established among
the parasite population (Table 1). Additionally, the pro-
portion of parasites of parasites carrying more than one
mutation at one or both genes (multiple mutants) proved
to be significantly elevated (Figure 1). In this respect,
attention is drawn to the observations that most of the
parasite population carried triple pfdhfr mutations (pfdhfr
51I/59R/108N) and that approximately half harbored the
quintuple mutant genotype pfdhfr 51I/59R/108N + pfdhfrMalaria Journal 2007, 6:35 http://www.malariajournal.com/content/6/1/35
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437G/540E (Figure 1) that have been shown to predict S/
P treatment failure in East Africa [4,5]. Indeed, in Mozam-
bique, a previous study reported that two mutations at
codon 59 in dhfr and codon 437 of dhps were actually
enough to significantly predict parasitological failure
[14]. Although in the present work no in vivo drug efficacy
screening was carried out, the above genotype data
appears to be consistent with previously reported S/P
treatment failure for this region [15].
In a recent survey in Malawi, the pfdhfr 164L mutation,
responsible for high level S/P resistance was reported [16].
In another study, which made use of a yeast expression
system allowing detection of low levels DHFR-TS alleles,
the presence of such mutants was also shown to occur in
Tanzania [17]. These reports may be interpreted as early
warning signs for a potential introduction of this geno-
type in Africa and prompted us to survey Mozambican
parasites for this mutation. Pfdhfr 164L mutants were not
identified in the present investigation however (Table 1),
corroborating previous findings indicating that this muta-
tion has not yet established itself in Africa [18,19].
Although the number of isolates analysed in the current
report may not be representative of the whole parasite
Table 1: Frequency of mutant, wild-type and mixed genotypes among the pfdhfr and pfdhps genes of Plasmodium falciparum from 
Maputo, Mozambique
GENE
Pfdhfr Pfdhps
Codon 51 59 108 164 437 540
M u t a n t  ( % )8 89 19 5 0 5 34 0
Wild-type (%) 7 6 2 100 35 41
M i x e d  ( % )5330 1 2 1 9
Frequencies of Plasmodium falciparum parasites from Maputo-Mozambique harboring more than one mutation in the pfdhfr and/ or pfdhps genes Figure 1
Frequencies of Plasmodium falciparum parasites from Maputo-Mozambique harboring more than one mutation in the pfdhfr and/
or pfdhps genes.Malaria Journal 2007, 6:35 http://www.malariajournal.com/content/6/1/35
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population in this area, numerous other mutant alleles of
pfdhfr and pfdhps, normally present in the region, were
observed (Table 1). One of the possible explanations for
the reported absence of this mutant could be that the
164L mutants may exist, but have not been detected using
the standard PCR-RFLP protocol. Alternative explanations
for the overall lack of this mutation among African para-
sites in general are put forward by Nzila and co-workers
[12]. Their main premise is that the 164L mutation comes
with a considerable fitness cost for the parasite and that
the genetic composition of African parasites is less able to
sustain it than their Asian counterparts. Nonetheless regu-
lar surveillance for this mutation should continue, in
order to curtail the impact of S/P resistance spread in the
African continent.
Conclusion
The observed high frequency of mutations in the S/P
resistance-associated  pfdhfr  and  pfdhps  genes raises evi-
dence-based concerns about the use of this drug as a com-
ponent of first-line antimalarial treatment in
Mozambique. The continued deployment of S/P will
increase drug-based selective pressure which progressively
raises the proportion of drug-resistant mutants and leaves
combination therapy highly dependant on the sole effect
of the S/P partner drug.
The study of the mechanisms associated with the selection
of 164L mutation and continuous monitoring of this and
other mutations are required, especially in areas where S/
P is extensively used as first-choice antimalarial treatment,
as in Maputo-Mozambique.
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